|
|
Time |
Source |
|
Announcement
|
|
| 29 Jul 2019 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF) |
| 18 Jul 2019 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased |
| 01 Jul 2019 |
4:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio |
| 07 Jun 2019 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces new leader of Pharmaceuticals Business Unit |
| 26 May 2019 |
11:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer |
| 24 May 2019 |
5:41 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families |
| |
5:32 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA) |
| 08 May 2019 |
11:20 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care |
| 24 Apr 2019 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded |
| 26 Mar 2019 |
11:35 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease |
| 22 Mar 2019 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis plans for Alcon spin-off on April 9, 2019 |
| 14 Mar 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces change in Sandoz leadership |
| 25 Feb 2019 |
10:55 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off |
| 30 Jan 2019 |
3:17 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018 |
| |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018 |
| 21 Dec 2018 |
1:53 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis successfully completes acquisition of Endocyte |
| 20 Dec 2018 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces new CEO of Oncology Business Unit |
| 13 Nov 2018 |
9:29 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London |
| 18 Oct 2018 |
6:02 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms |
| |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth |
| 29 Aug 2018 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma |
| 23 Aug 2018 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation |
| 14 Aug 2018 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer |
| 27 Jul 2018 |
1:53 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab) |
| 18 Jul 2018 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company |
| 29 Jun 2018 |
1:10 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe |
| |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn |
| 01 Jun 2018 |
1:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion |
| |
12:40 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine |
| 18 May 2018 |
12:14 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention |
| 16 May 2018 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces changes to the Executive Committee |
| 01 May 2018 |
9:26 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma |
| |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis provides update on proposed acquisition of AveXis |
| 19 Apr 2018 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer |
| |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis delivered a strong first quarter and acted to become a more focused medicines company |
| 17 Apr 2018 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis tender offer for AveXis commences |
| 09 Apr 2018 |
5:45 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader |
| 27 Mar 2018 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities |
| 01 Feb 2018 |
9:05 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A. |
| 26 Jan 2018 |
6:02 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors |
| 24 Jan 2018 |
6:02 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017 |
| |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase |
| 11 Jan 2018 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis appoints Elizabeth Barrett as Oncology Head |
| 15 Dec 2017 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces Oncology head to retire |
| 13 Nov 2017 |
5:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants |
| |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event |
| |
2:51 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness |
| 30 Oct 2017 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio |
| 24 Oct 2017 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis delivered growth on top and bottom line in all divisions in Q3 |
| 04 Sep 2017 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. |
| 30 Aug 2017 |
4:04 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice |
| 28 Aug 2017 |
8:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned |
| |
8:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk |
| 18 Jul 2017 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products |
| 12 Jul 2017 |
10:24 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL |
| 22 Jun 2017 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack |
| 20 Jun 2017 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval |
| 31 May 2017 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (68CT) |
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018 |